Krešimir Tomić, Kristina Katić, Zoran Gatalica, Gordan Srkalović, Maja Pezer Naletilić, Eduard Vrdoljak, Semir Vranić
{"title":"Immunotherapy of endometrial cancer: a review of recent advances.","authors":"Krešimir Tomić, Kristina Katić, Zoran Gatalica, Gordan Srkalović, Maja Pezer Naletilić, Eduard Vrdoljak, Semir Vranić","doi":"10.1080/1750743X.2026.2644799","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy with immune checkpoint inhibitors (ICI) has become a transformative pillar in cancer treatment, offering significant improvements in survival and reducing treatment-related side effects compared to traditional therapies. In gynecologic cancers, ICIs have transformed the treatment of endometrial (EC) and cervical cancers, whereas they have not demonstrated clinical benefit in ovarian cancer. This review examines the current state of ICI advancements in EC. Given the unique immunological characteristics of EC, a comprehensive understanding of advancements is crucial for optimizing decision-making and patient outcomes. While ICIs have demonstrated robust and durable efficacy in dMMR/MSI-H EC, the magnitude of benefit in pMMR disease remains modest. Additionally, we examine promising future directions, including personalized immunotherapy approaches and novel combination therapies (e.g. antibody-drug conjugates, PARP inhibitors, antiangiogenic drugs).</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"187-203"},"PeriodicalIF":2.3000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154956/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2026.2644799","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Immunotherapy with immune checkpoint inhibitors (ICI) has become a transformative pillar in cancer treatment, offering significant improvements in survival and reducing treatment-related side effects compared to traditional therapies. In gynecologic cancers, ICIs have transformed the treatment of endometrial (EC) and cervical cancers, whereas they have not demonstrated clinical benefit in ovarian cancer. This review examines the current state of ICI advancements in EC. Given the unique immunological characteristics of EC, a comprehensive understanding of advancements is crucial for optimizing decision-making and patient outcomes. While ICIs have demonstrated robust and durable efficacy in dMMR/MSI-H EC, the magnitude of benefit in pMMR disease remains modest. Additionally, we examine promising future directions, including personalized immunotherapy approaches and novel combination therapies (e.g. antibody-drug conjugates, PARP inhibitors, antiangiogenic drugs).
期刊介绍：
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
